Micro Hospitals
Market Cap
₹1,357 ₹1,357 Cr.
P/E
85.71
PEG
6.21
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis depends on sustained growth in occupied bed days, supported by higher hospital activity and realization; quarterly bed-day and average-revenue-per-bed disclosures are the key validation triggers.

The bull path combines stronger patient throughput with higher realization, while the bear path reflects weaker bed-day growth together with pricing or mix pressure.

Key Ratios

Debt to Equity
Debt to Equity
0.15
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
5.74 %
Institutions
Institutions
5.44 %
Market cap
Market cap
1,357 Cr
No. of Shareholders
No. of Shareholders
18,301
OPM (%)
OPM (%)
26.42 %
PE
PE
85.71
Prom Holding
Prom Holding
71.45 %
ROCE (%)
ROCE (%)
40.67
ROE (%)
ROE (%)
36.29
Sales
Sales
101 Cr
  • Guj. Kidney & Super
  • Fortis MalarHospital
  • Yatharth Hospital
Last updated on 24 Aug 2026
  • Gujarat Kidney And Super Speciality, born Vihaan Medicare in 2019, built via serial acquisitions into multi-town Gujarat hospitals; flagship Vadodara renal/urology; ~389 beds.
  • Q1FY27 standalone shows strain: revenue down 19%, PAT down 48% at parent.
  • Hospital services plus ancillary pharmacy drive earnings; ~90% revenue from insured walk-ins; no customer concentration.
  • Acquisition-led expansion across Gujarat micro-markets, now overseas; building Vadodara women's hospital and Bharuch unit.
  • IPO-funded with unspent capex and inorganic budgets; Rs9,073 lakh goodwill overhang risks impairment.
  • In post-IPO digestion phase; near-term earnings hinge on same-perimeter margins, not headline growth.
  • Founder-centric deals with no non-compete on promoter ventures; empty CEO slot and repeat compliance misses dent credibility.
  • Blue Tree 51% completion by ~early Sep 2026
    adds first overseas leg for Rs19.84Cr; Dubai consolidation timeline resolved.
  • First full-perimeter quarter ~early-mid Nov 2026
    reveals full-quarter acquired contribution, margins vs FY26 ~34% and any goodwill impairment.
  • Permanent CEO hire next boards (~Nov 2026)
    decides external hire vs MD dual role; further deferral extends governance drag.
  • New Vadodara women's hospital No stated COD
    Rs30.10Cr IPO object; pace, cost vs quotes and scope show deployment discipline.
  • Bharuch hospital via new unit No stated COD
    new expansion leg; funding mix and scale vs Vadodara shape leverage.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
98
52W Range
High
183
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Payment Mode

Operational Metrics

    Select a Metric
    • Average Daily Revenue Per Occupied Bed (Rs)
    • Hospital Occupancy Rate (%)
    • Average Length Of Stay (Days)
    • Operational Beds (.)
    • Number of Outpatient Visits - Quarterly (.)

    Peer Comparison

    FAQs on Gujarat Kidney And Super Speciality Ltd. Business

    Gujarat Kidney and Super Speciality operates a chain of mid-sized multi-speciality hospitals, providing integrated healthcare services, with a focus on secondary (which are surgical services) and tertiary care (which are super speciality surgical services).

    Guj. Kidney & Super major competitors are Fortis MalarHospital, Yatharth Hospital, GPT Healthcare, Jupiter Life Line, Narayana Hrudayalay., KMC Speciality Hosp., Aster DM Quality.
    Market Cap of Guj. Kidney & Super is ₹1,347 Crs.
    While the median market cap of its peers are ₹9,143 Crs.

    Guj. Kidney & Super seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation Aug
    Conference Call
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material